Metformin reduces lipid accumulation in HepG2 cells via downregulation of miR-33b

Arch Physiol Biochem. 2022 Apr;128(2):333-340. doi: 10.1080/13813455.2019.1680700. Epub 2019 Nov 5.

Abstract

Introduction: Here, we aimed to investigate whether the beneficial effects of metformin on lipid accumulation is mediated through regulation of miR-33b.

Methods: The expression of the genes and miRNAs and protein levels were evaluated using real-time PCR and western blot, respectively. To investigate the potential role of miR-33b in lipid accumulation, the mimic of the miR-33b was transfected into HepG2 cells.

Results: We found that metformin reduces high glucose-induced lipid accumulation in HepG2 cells through inhibiting of SREBP1c and FAS and increasing the expression of CPT1 and CROT. Overexpression of miR-33b significantly prevented the decreasing effect of metformin on lipid content and intra and extra triglyceride levels. Importantly, miR-33b mimic inhibited the increasing effects of metformin on the expression of CPT1 and CROT.

Conclusion: These findings suggest that metformin attenuates high glucose-induced lipid accumulation in HepG2 cell by downregulating the expression of miR-33b.

Keywords: HepG2; high glucose; metformin; miR-33b lipogenesis; miRNA.

MeSH terms

  • Down-Regulation
  • Hep G2 Cells
  • Humans
  • Lipids
  • Metformin* / pharmacology
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism

Substances

  • Lipids
  • MicroRNAs
  • Metformin